By Stephen Simon
Artificial intelligence company Anthropic has quietly established a physical biology laboratory as it expands its ambitions in drug research and scientific discovery.
The company, known for developing the Claude AI system, has created a laboratory in the San Francisco Bay Area where it can conduct physical biological experiments rather than relying entirely on computer-based simulations.
According to Reuters, Anthropic is exploring ways for its AI models to direct robots and perform tasks in laboratory environments, potentially allowing artificial intelligence to play a greater role in scientific research.
The company’s move represents an expansion beyond the traditional use of AI for analysing information, writing software and generating content. It signals growing interest among technology companies in applying advanced AI systems to real-world scientific work.
Anthropic’s life sciences division is reportedly focused on using AI to accelerate research while stopping short of conducting clinical trials or directly competing with pharmaceutical companies.
The company is also studying how AI can help scientists understand biological processes and develop new approaches to drug discovery.
The development comes as major technology companies increase investment in AI-powered science, with researchers exploring whether advanced models can reduce the time and cost required to make discoveries in areas such as medicine, biology and chemistry.
However, the growing use of AI in biological research is also expected to raise questions about safety, regulation, scientific oversight and the extent to which machines should be allowed to control physical experiments.
Anthropic’s laboratory therefore marks another step in the rapidly developing relationship between artificial intelligence and scientific research, as technology companies increasingly seek applications for AI beyond the digital world.
